Literature DB >> 18953093

Effects of peripheral or central GLP-1 receptor blockade on leptin-induced suppression of appetite.

A Nowak1, E Bojanowska.   

Abstract

Leptin and glucagon-like peptide-1 (GLP-1) were proved to act in concert to control the activity of feeding centres. Since leptin receptor was identified in the gut endocrine L cells and neurons producing GLP-1, we have checked whether GLP-1 mediates the effects of leptin on feeding and drinking behaviour. To this aim, an intraperitoneal or intracerebroventricular injection of exendin (9 - 39), a GLP-1 antagonist, (50 or 10 microg per rat, respectively) followed by leptin (100 or 5 microg per rat, respectively) was made and 24-hour food intake and body weight changes were measured. Previous injection of exendin (9-39) completely abolished the supressory effect of peripheral leptin on food intake and body weight gain. Moreover, exendin (9-39) significantly attenuated the effect of intracerebroventricular leptin on food but not water consumption. It is concluded that intact GLP-1 signalling is necessary to mediate the effect of leptin on food intake in the rat. Conversely, leptin seems to affect the thirst center function independently of GLP-1. Also, these findings produce further evidence for close interactions between long- and short-term factors regulating the activity of feeding centres.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18953093

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  10 in total

Review 1.  Counterregulation of insulin by leptin as key component of autonomic regulation of body weight.

Authors:  Katarina T Borer
Journal:  World J Diabetes       Date:  2014-10-15

Review 2.  Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects.

Authors:  Matthew R Hayes
Journal:  Physiol Behav       Date:  2012-02-17

Review 3.  GLP-1 and energy balance: an integrated model of short-term and long-term control.

Authors:  Jason G Barrera; Darleen A Sandoval; David A D'Alessio; Randy J Seeley
Journal:  Nat Rev Endocrinol       Date:  2011-06-07       Impact factor: 43.330

4.  Jejunal linoleic acid infusions require GLP-1 receptor signaling to inhibit food intake: implications for the effectiveness of Roux-en-Y gastric bypass.

Authors:  Megan J Dailey; Alexander A Moghadam; Timothy H Moran
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-09-13       Impact factor: 4.310

5.  Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms.

Authors:  S E Kanoski; Z Y Ong; S M Fortin; E S Schlessinger; H J Grill
Journal:  Diabetes Obes Metab       Date:  2015-01-08       Impact factor: 6.577

Review 6.  GLP-1 and weight loss: unraveling the diverse neural circuitry.

Authors:  Scott E Kanoski; Matthew R Hayes; Karolina P Skibicka
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-03-30       Impact factor: 3.619

7.  Roux-en-Y gastric bypass in rats increases sucrose taste-related motivated behavior independent of pharmacological GLP-1-receptor modulation.

Authors:  C M Mathes; M Bueter; K R Smith; T A Lutz; C W le Roux; A C Spector
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-14       Impact factor: 3.619

8.  Hindbrain leptin and glucagon-like-peptide-1 receptor signaling interact to suppress food intake in an additive manner.

Authors:  S Zhao; S E Kanoski; J Yan; H J Grill; M R Hayes
Journal:  Int J Obes (Lond)       Date:  2012-01-17       Impact factor: 5.095

Review 9.  Obesity and appetite control.

Authors:  Keisuke Suzuki; Channa N Jayasena; Stephen R Bloom
Journal:  Exp Diabetes Res       Date:  2012-08-01

10.  Activation of the GLP-1 receptors in the nucleus of the solitary tract reduces food reward behavior and targets the mesolimbic system.

Authors:  Jennifer E Richard; Rozita H Anderberg; Andreas Göteson; Fiona M Gribble; Frank Reimann; Karolina P Skibicka
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.